Glenn Rockman is Founder and Managing Partner at Adjuvant Capital, a life sciences investment fund focused on financing the development of new interventions for historically overlooked global public health challenges such as cholera, malaria, Lassa fever, and post-partum hemorrhage. Prior to Adjuvant, Glenn launched and then co-managed the Global Health Investment Fund (GHIF), which was sponsored by the Bill & Melinda Gates Foundation and structured by J.P. Morgan’s Social Finance unit, where Glenn was an Executive Director.

At Adjuvant, Glenn oversees the firm’s investments in Codagenix (board member), X-Vax Technology (board observer), InDevR (board member), and Themis Bioscience (board member). He is also actively engaged with the Research Investment for Global Health Technology Fund (RIGHT Fund) as a board member and a champion of leveraging the strengths of South Korea’s life sciences industry to bring new public health innovations to market. He is still active on a number of GHIF projects as well, including board seats on a number of innovative life sciences companies such as Univercells and EuBiologics (listed on the KOSDAQ exchange in 2017: 206650.KQ). Glenn also represented GHIF’s interests as a director at IanTech, which was acquired by Carl Zeiss Meditec in 2018.

Prior to his GHIF/Adjuvant roles, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, and other non-profit organizations. He earned an AB in public policy from the Woodrow Wilson School of Public & International Affairs at Princeton University.